In the early stages of development, a tumor is limited by the simple physics of diffusion. Without a dedicated blood supply, a malignant mass cannot grow beyond a few millimeters before its core begins to starve. To overcome this metabolic ceiling, tumors undergo an "angiogenic switch," hijacking the body’s physiological wound-healing mechanisms to build a private infrastructure of blood vessels. As Huaiping Shi notes, this continuous formation of new vessels is not just a side effect of cancer, but a requirement for its survival and expansion.
The Paracrine Recruitment Mechanism
Tumors do not typically build their own vessels from scratch. Instead, they act as master recruiters, sending out molecular signals to manipulate nearby healthy tissue. This process, known as paracrine-mediated angiogenesis, involves the secretion of growth factors that signal neighboring endothelial cells to migrate toward the tumor and organize into tubular structures.
Tianli Yang et al. demonstrate that this recruitment is often triggered by the tumor's interaction with the extracellular matrix. For instance, the Sigma 1 receptor (Sig1R) can form a complex with $\beta$-integrin to translate environmental signals into the secretion of vascular endothelial growth factors (VEGF). Similarly, Dong Zhang et al. highlight that even non-cancerous cells, such as primed adipose-derived stem cells, can facilitate this process by creating a "pro-angiogenic environment" through the concentrated secretion of VEGF and bFGF.
Molecular Drivers of the Angiogenic Switch
The decision to build new vasculature is governed by complex intracellular signaling pathways. Several researchers have identified specific "master regulators" that force cancer cells to pump out angiogenic factors:
- LncRNAs and Hypoxia: Jinduan Lin et al. found that long non-coding RNAs like UBE2CP3 activate the ERK1/2/HIF-1α pathway, which is sensitive to low oxygen levels and directly triggers VEGFA secretion.
- Kinase Signaling: Qingyue Ma et al. identified Aurora kinase A (AURKA) as a primary driver in uveal melanoma, operating through the JAK2/STAT3 pathway to fuel vessel growth.
- Transcription Factors: Sheng‐Zhang Lin et al. showed that the NF-κB pathway regulates the genes responsible for both tumor growth and the recruitment of new blood supply.
Structural Inefficiency and the Path to Metastasis
Unlike the orderly, hierarchical branching of healthy vasculature, tumor-induced angiogenesis produces a chaotic and dysfunctional network. Using ultra-high-field 7 Tesla MRI, Alexander Radbruch et al. quantified this "chaotic plumbing." They found that while tumor vessels have a significantly higher total surface area—providing more interface for nutrient exchange—they are characterized by shorter branch lengths and a disorganized architecture.
This structural messiness has a dark utility for the cancer. Wanqing Li explains that these new vessels are often highly permeable. This leakiness not only facilitates nutrient delivery but also creates accessible "highways" for cancer cells to enter the systemic circulation, facilitating metastasis to distant organs.
Therapeutic Strategies: Cutting the Supply Line
Because tumors are so dependent on this recruited infrastructure, disrupting angiogenesis has become a cornerstone of modern oncology. Research generally follows two paths: inhibiting the receptors that receive growth signals or "de-arming" the signals themselves.
Traditional inhibitors like Axitinib target the VEGFR-2 receptor to block endothelial cell activation, though Na Wei et al. suggest that developing more selective derivatives could enhance efficacy. Interestingly, Michal Munster et al. discovered that anti-VEGF therapies can work by "de-arming" tumor-derived microparticles (TMPs), preventing them from carrying the pro-angiogenic cargo needed to recruit bone marrow cells for vessel construction.
Furthermore, natural compounds are being explored for their multi-target potential. For example, extracts from Ligularia fischeri (Jae Hyeon Kim et al.) and Broussonetia kazinoki (Young‐Rak Cho et al.) have been shown to simultaneously hit multiple signaling pathways (like Akt and ERK), making it harder for the tumor to bypass the blockade and continue its vascular recruitment.
Key Foundational Work
Antitumor Activity of Emodin against Pancreatic Cancer Depends on Its Dual Role: Promotion of Apoptosis and Suppression of Angiogenesis (2012) — contributed 1 concept elements to this direction.
Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer (2007) — contributed 1 concept elements to this direction.